Pure Global
NCT01146444

Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)

Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus
Spirig Pharma Ltd.·ClinicalTrials.gov·otherCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
UV A and B irradiation
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Spirig Pharma Ltd.
Location
Münster, Germany
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2009
End date
Nov 01, 2012
Enrollment
20 participants
Primary outcome

Prevention of skin lesions following standardized photoprovokation with UVA/UVB light in patients with CLE

Summary

Part I: to investigate the efficacy of different sunscreens in the prevention of skin lesions
 following standardized photoprovocation with Ultraviolet A/Ultraviolet B (UVA/UVB) light in
 patients with CLE.
 
 Part II: to evaluate the influence of different sunscreens on the expression of biomarkers in
 the skin of patients with CLE and of Healthy Controls following UV irradiation.

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01146444
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01146444 through Pure Global AI's free database. This phase not specified trial is sponsored by Spirig Pharma Ltd. and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.